NASDAQ:EARS - Auris Medical Stock Price, Forecast & News

Auris Medical trades on the NASDAQ under the ticker symbol "EARS."

Auris Medical shares reverse split on the morning of Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 30th 2019. An investor that had 100 shares of Auris Medical stock prior to the reverse split would have 5 shares after the split.

Auris Medical Holding Ltd (NASDAQ:EARS) posted its earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.80) by $1.60. View Auris Medical's Earnings History.

Auris Medical is scheduled to release their next quarterly earnings announcement on Thursday, December 12th 2019. View Earnings Estimates for Auris Medical.

1 brokers have issued 1-year target prices for Auris Medical's stock. Their forecasts range from $100.00 to $100.00. On average, they expect Auris Medical's stock price to reach $100.00 in the next year. This suggests a possible upside of 7,146.4% from the stock's current price. View Analyst Price Targets for Auris Medical.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Auris Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Auris Medical.

Media headlines about EARS stock have trended somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Auris Medical earned a news impact score of 0.7 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Auris Medical.

Auris Medical saw a decline in short interest in November. As of November 15th, there was short interest totalling 39,800 shares, a decline of 38.0% from the October 31st total of 64,200 shares. Based on an average daily trading volume, of 133,500 shares, the short-interest ratio is presently 0.3 days. Currently, 2.5% of the company's stock are sold short. View Auris Medical's Current Options Chain.

Some companies that are related to Auris Medical include Cyclacel Pharmaceuticals (CYCC), Sunwin Stevia International (SUWN), Lipocine (LPCN), HST Global (HSTC), Trillium Therapeutics (TRIL), NeuroVive Pharmaceutical (NEVPF), GT Biopharma (GTBP), Integrated BioPharma (INBP), Acura Pharmaceuticals (ACUR), Rexahn Pharmaceuticals (REXN), BENITEC BIOPHAR/S (BNTC), Uluru (ULUR), Reliv International (RELV), Novus Therapeutics (NVUS) and Tetraphase Pharmaceuticals (TTPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Auris Medical investors own include Helios and Matheson Analytics (HMNY), TransEnterix (TRXC), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), RXi Pharmaceuticals (RXII), Flexion Therapeutics (FLXN), Sophiris Bio (SPHS), Iconix Brand Group (ICON), Magnegas Applied Tchnlgy Sltns (MNGA) and Novavax (NVAX).

Auris Medical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (8.96%).

EARS stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC.

Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EARS stock can currently be purchased for approximately $1.38.

Auris Medical has a market capitalization of $2.59 million. The biotechnology company earns $-11,750,000.00 in net income (profit) each year or ($14.80) on an earnings per share basis. Auris Medical employs 9 workers across the globe.View Additional Information About Auris Medical.

The official website for Auris Medical is http://www.aurismedical.com/.

Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]